2020 and Beyond: Payer Strategies for the Future

Roshawn Blunt, managing director of 1798, a Fingerpaint company, shared her insights on market access challenges as well as changes in legislature that are impacting the access to pharmaceutical brands across the country. Blunt highlighted in PM360 that “biosimilars continue to take market share from reference products, triggering increased competition.” The response to this impacts not only originators, but also payers, which presents “a challenge that biosimilars cannot overcome via low WAC alone.”